J
Judith Balmana Gelpi
Researcher at Hebron University
Publications - 4
Citations - 228
Judith Balmana Gelpi is an academic researcher from Hebron University. The author has contributed to research in topics: Olaparib & Metastatic breast cancer. The author has an hindex of 3, co-authored 4 publications receiving 126 citations.
Papers
More filters
Journal ArticleDOI
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
Nadine Tung,Judy C. Boughey,Lori J. Pierce,Mark E. Robson,Isabelle Bedrosian,Jill R. Dietz,Anthony E. Dragun,Judith Balmana Gelpi,E Hofstatter,Claudine Isaacs,Ismail Jatoi,Elaine Kennedy,Jennifer K. Litton,Nina A. Mayr,Rubina Qamar,Mark G. Trombetta,Brittany E. Harvey,Mark R. Somerfield,Dana Zakalik +18 more
TL;DR: Recommendations for management of patients with breast cancer (BC) with germline mutations in BC susceptibility genes are developed based on a systematic review of the literature and a formal consensus process.
Journal ArticleDOI
Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).
Nicholas C. Turner,Melinda L. Telli,Hope S. Rugo,Audrey Mailliez,Johannes Ettl,Eva-Maria Grischke,Lida A. Mina,Judith Balmana Gelpi,Peter A. Fasching,Sara A. Hurvitz,Andrew M Wardley,Colombe Chappey,Wendy Verret,Alison L. Hannah,Mark E. Robson +14 more
TL;DR: ABRAZO (NCT02034916) is a 2-cohort, 2-stage phase 2 study of TALA (1 mg/d) following platinum-based therapy or ≥ 3 platinum-free cytotoxic-based regimens in pts with locally advanced or metastatic breast cancer (MBC) and gBRCA1/2mutation previously exposed to platinum or multiple prior cytot toxic regimens.
Journal ArticleDOI
OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
Andrew Tutt,Judy Garber,Bella Kaufman,Giuseppe Viale,Debora Fumagalli,Priya Rastogi,Richard D. Gelber,Evandro de Azambuja,Anitra Fielding,Judith Balmana Gelpi,Karen A. Gelmon,Nigel Baker,Amal Arahmani,Elżbieta Senkus-Konefka,Eleanor Mc Fadden,Vassiliki Karantza,Sunil R. Lakhani,Greg Yothers,Christine Campbell,Charles E. Geyer +19 more
TL;DR: OlympiA, a randomized, double-blind, phase III study, enrolled pts with gBRCAm and HER2-negative (TNBC or hormone-receptor+ [HR+]) high-risk EBC after primary local treatment and ACT/NACT, and showed a significant benefit of OL vs PL for IDFS.
Journal ArticleDOI
Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.
Karen A. Gelmon,Peter A. Fasching,Fergus J. Couch,Judith Balmana Gelpi,Suzette Delaloge,Intidhar Labidi-Galy,James Bennett,Susan McCutcheon,Sabine Ano,Joyce O'Shaughnessy +9 more
TL;DR: OlympiAD demonstrated the benefit of olaparib over standard of care in patients with HER2-negative (HER2-) metastatic breast cancer and germline BRCA mutat...